Week in Review 1/23

 

Welcome and thanks for reading!

In this review, I will make a summary of important and interesting news and events over the last week related to my portfolio holdings. Also, I will put together some interesting articles from other websites that caught my attention during the past week.

Received Dividends:

January 3, 2023

• € 20.13 – UGI Corporation (UGI)
• € 12.29 – Baxter International Inc. (BAX)
• € 24.61 – Best Buy Co., Inc. (BBY)
• € 69.52 – TELUS Corporation (TSE:T)

January 4, 2023

• € 10.58 – Kimberly-Clark Corporation (KMB)

January 5, 2023

• € 42.26 – Brookfield Renewable (BEP, BEPC)
• € 57.32 – Brookfield Infrastructure (BIP, BIPC)

Week 1: Total net dividends € 236.71

Dividend income is reported after the deduction of taxes. Check more at my Monthly Dividend sheet.

Portfolio Holdings News:

January 3, 2023

• NCC AB (NCC) to refurbish 303 residential units for BO-VEST in Copenhagen; NCC has been contracted by BO-VEST and Vridsløselille Andelsboligforening to refurbish 303 residential units in the Blokland area of Albertslund on the outskirts of Copenhagen in Denmark. The order value is approximately SEK 440 million.

• NCC signs construction contract to build Park Central in Gothenburg; NCC has signed an agreement for the construction of Park Central. This project comprises a station and office building totaling approximately 40,000 square meters and is to be constructed directly adjacent to Gothenburg Central Station and the West Link (Västlänken) Centralen station.

• Viatris Inc. (VTRS) Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences; VTRS announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7 as part of Viatris' strategic update. Former Oyster Point Pharma CEO, Jeffrey Nau, Ph.D., MMS, will lead the new division.

• Canadian National Railway Company (CNR) ratifies new agreement for rail traffic controllers in Canada; CNR announced today that on December 23, 2022, the Teamsters Canada Rail Conference ratified a new collective agreement. The agreement covers approximately 160 rail traffic controllers in Canada. The agreement came into effect on January 1, 2023 and includes adjustments to wages of 3% in 2023, 3% in 2024 and 2.5% in 2025 and other benefits. The agreement is in effect until December 31, 2025.

January 4, 2023

• Orion Corporation (ORNBV) and Amneal enter strategic partnership; ORNBV receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand. Under the terms of the agreement, Orion is granted exclusive licence to commercialise and sell Amneal’s generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include a mix of generic products commercially available in the U.S. today, as well as selected pipeline products currently under development. Initial products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years.

• UGI Corporation (UGI) Announces Investment in Additional Renewable Natural Gas Projects in South Dakota; UGI announced that MBL Bioenergy has entered an agreement to develop its second and third clusters of dairy manure waste to renewable natural gas (“RNG”) projects in South Dakota. In total, these additional projects will represent approximately $150 million of investment by MBL Bioenergy, of which 100% of the funds will be provided by UGI Energy Services, LLC (“UGIES”), a subsidiary of UGI. MBL Bioenergy is a joint venture partnership between UGIES, Sevana Bioenergy and a subsidiary of California Bioenergy (“CalBio”) with the sole purpose of developing RNG projects in South Dakota.

• Enbridge Inc. (ENB) Announces Renewal of Normal Course Issuer Bid; ENB announced that the Toronto Stock Exchange (TSX) has approved the Company's new normal course issuer bid (NCIB) to purchase, for cancellation, up to 27,938,163 of its outstanding common shares to an aggregate amount of up to $1.5 billion.

January 5, 2023

• Walgreens Boots Alliance, Inc. (WBA) Reports Fiscal 2023 First Quarter Results; WBA reports first quarter Non-GAAP EPS of $1.16, a 30.8% decline from last year but $0.02 ahead of estimates. Revenue of $33.38 billion beats analyst estimates by $340 million but decreased 1.5% versus the same quarter last year. For FY2023 management maintaining adjusted EPS guidance of $4.45 to $4.65 and raised sales guidance to $133.5 billion to $137.5 billion.

• Lockheed Martin Corporation (LMT) was awarded a $139.65M cost-plus-incentive-fee, cost-plus-fixed-fee, cost-only, and firm-fixed-price contract for AEGIS fielding and sustainment. LMT was also awarded a $130.74M cost-plus-incentive-fee, cost-plus-fixed-fee, firm-fixed-price, and fixed-price-award-fee modification to previously awarded contract N00024-13-C-5116 for AEGIS Combat System engineering agent efforts for the continued performance of engineering, development, and delivery of AEGIS Weapon System capabilities for FFG 62, and Coast Guard OPC3 Athena.

• Raytheon Technologies Corporation (RTX) was awarded a $208.74M firm-fixed-price contract for the Naval Strike Missile Coastal Defense System for the Republic of Romania.

• LTC Properties, Inc. (LTC) Invests $128 Million North Carolina; LTC announced an approximate $128 million investment in 12 assisted living/memory care properties (a combined 937 licensed beds in 568 units). The communities are located throughout North Carolina and are currently owned and operated by an existing LTC partner.

January 6, 2023

• AbbVie Inc. (ABBV) expects IPR&D and milestones expense to impact Q4, full-year 2022 results; ABBV that GAAP earnings and adjusted non-GAAP earnings for Q4 2022 and full-year 2022 will be negatively impacted by an acquired IPR&D and milestones expense of $243M. That translates to a $0.14 impact to both GAAP and non-GAAP diluted EPS. For Q4 2022, management now expects adjusted diluted EPS of $3.51-$3.55. For the year, EPS is projected at $13.70-$13.74.

• Baxter International Inc. (BAX)Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders; BAX announced a plan to spin off the company's Renal Care and Acute Therapies global business units (GBUs) into an independent, publicly traded company. BAX intends to complete the proposed spinoff in 12 to 18 months, subject to certain closing conditions, including the final approval from its Board of Directors.

Articles that caught my attention:

• Undervalued Dividend Growth Stock of the Week: Microsoft (MSFT) by Jason Fieber, Mr. Free at 33, at Daily Trade Alert
• Financial Goals For 2023 — 9 Personal Finance & Investing Goals Graham at Reverse the Crush
• 10 Rules Of Dividend Investing that Make Money Now by Tom at Dividends Diversify
• Okay, I'm A High Yield Chaser, So What? by Brad Thomas at Seeking Alpha
• I'm Doubling My Portfolio REIT Allocation For 2023 - Here's Why by Wolf Report at Seeking Alpha
• Canadian Dividend Aristocrats – The Top Aristocrats in January 2023 by Dan Kent at Stocktrades
• What Is A Good Dividend Yield? by Nathan Parsh at Sure Dividend
• McDonald's Corporation (MCD) Dividend Stock Analysis by D4L at Dividend Growth Stocks
• Altria Vs. Philip Morris: One's Way Better by Jonathan Weber at Seeking Alpha
• V.F. Corporation's 7.39% Yield: Sustainable Or Value Trap? by Heavy Moat Investments at Seeking Alpha
• Medical Properties: Will There Be A Dividend Cut In 2023? by On the Pulse at Seeking Alpha
• Enbridge: Sleep Well With This 7% Yield by Gen Alpha at Seeking Alpha
• These 6 Stocks Just Boosted Their Dividends, Again! by Jason Fieber, Mr. Free at 33, at Daily Trade Alert
• 2023 Dogs of the Dow: All 10 High-Yielding Stocks Analyzed by Simply Safe Dividends
• 14 High-Yield Blue-Chips Perfect For 2023 by Dividend Sensei at Seeking Alpha
• 5 Relatively Safe And Cheap Dividend Stocks To Invest In - January 2023 by Financially Free Investor at Seeking Alpha

Thanks for stopping by, have a nice next week!

Tweet